Patients on brand-name tirzepatide without supplemental B12 should have B12 levels monitored periodically, especially after 6 to 12 months of treatment
With disease activity categorized on a scale of 0 to 3 (remission to severe), the group averages changed by -0.03 points for those using GLP-1 agonists versus +0.21 for non-users ( P =0.03)
Crh, corticotropin-releasing hormone-expressing
Doi: Manna C, Officioso A, Trojsi F, Tedeschi G, Leoncini S, Signorini C, Ciccoli L, De Felice C (2016) Increased Non-Protein Bound Iron in Down Syndrome: Contribution to Lipid Peroxidation and Cognitive Decline
J Am Geriatr Soc 65(9):19881995 Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N et al (2020) Bimagrumab vs optimized standard of care for treatment of sarcopenia in Community-Dwelling older adults: A randomized clinical trial